Nearly $12 million in cash and investment
Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation 12/20/2021
PHARMATHER ENTERS INTO PROCESS DEVELOPMENT AGREEMENT WITH LTS LOHMANN FOR KETAMINE MICRONEEDLE PATCH |
5/5/2022